Trial Profile
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Vilaprisan in Subjects With Decreased Renal Function in Comparison With Matched Subjects With Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2020
Price :
$35
*
At a glance
- Drugs Vilaprisan (Primary)
- Indications Endometriosis; Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Bayer
- 30 Mar 2020 Results published in the Journal of Clinical Pharmacology
- 26 Feb 2019 Status changed from active, no longer recruiting to completed.
- 07 Jan 2019 Planned End Date changed from 28 Nov 2018 to 31 Jan 2019.